 |
|
|
| |
High Sustained Virologic Response Rates at 24 Weeks in Participants With Chronic HCV GT1, 2, or 3 Infection Following 16 Weeks of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) Plus Ribavirin After Having Failed 8 Weeks of a Triple Drug Regimen (Part C of C-CREST-1 & 2)
|
| |
| |
Reported by Jules Levin
EASL 2017 April19-21 Amsterdam Netherlands
Lawrence Serfaty1; Stephen Pianko2; Ziv Ben Ari3; Alex L. Laursen4; Jesper Hansen5; Hsueh-Cheng Huang6; Shu Jin6; Jennifer Bourque6; Hong Liu6; Anjana Grandhi6; Mandy Su6; Noel Gendrano6; Doreen Fernsler6; Frank Dutko6; Bach-Yen T. Nguyen6; Janice Wahl6; Eliav Barr6; Wendy W. Yeh6; Rebeca Plank6; Joan R. Butterton6; Edward J. Gane7
1Saint-Antoine Hospital, Paris, France; 2Monash Health, Clayton, VIC, Australia; 3Sheba Medical Center, Tel Hashomer, Israel; 4Aarhus University Hospital, Skejby, Aarhus N, Denmark; 5Aalborg University Hospital, Aalborg, Denmark; 6Merck & Co., Inc., Kenilworth, NJ, USA; 6Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
